Russell Alice

From: nrescommittee.london-westminster@nhs.net <noreply@harp.org.uk>

Sent: 05 July 2019 11:46

To: Smith Catherine (Dermatology); Russell Alice

Cc: nhsq.nrspcc@nhs.net; research-permissions@wales.nhs.uk

Subject: IRAS 71048. Amendment confirmation of REC Validation, categorisation and

implementation information

Attachments: 11h08027_am16_SL27

_Acknowledgement_of_a_valid_notice_of_a_substantial_amendment_sq050719.pdf

Apologies that this got lost in our inbox- I have started the 35 day clock from the date submitted 06/06

Amendment Confirmation of REC Validation, Categorisation and Implementation Information

Dear Dr Smith,

IRAS Project ID:	71048
Short Study Title:	Bio-markers of Systemic Treatment Outcomes in Psoriasis
Date complete amendment submission received:	06 June 2019
Amendment No./ Sponsor Ref:	5 - 02/05/2019
Amendment Date:	06 June 2019
Amendment Type:	Substantial
England and/or Wolce	HRA and HCRW Approval for the amendment is pending. HRA and HCRW Approval for the amendment will be separately confirmed by email. 35 days from date amendment information together with this email, is supplied to participating organisations (provided HRA and HCRW Approval for the amendment is in place and conditions are met)
Implementation date in NHS/HSC organisations in Northern Ireland and/or Scotland	10/07 (providing conditions are met)
For NHS/HSC R&D Office information	
Amendment Category	A

Thank you for submitting an amendment to your project. We have now categorised your amendment and please find this, as well as other relevant information, in the table above.

Please also find attached a copy of the REC validation letter for the submitted amendment.

What should I do next?

Please read the information in <u>IRAS</u>, which provides you with information on how and when you can implement your amendment at NHS/HSC sites in each nation, and <u>what actions you should take now.</u>

If you have participating NHS/HSC organisations in any other UK nations that are affected by this amendment please note that **we will** forward the amendment submission to the relevant national coordinating function(s).

If not already provided, please email to us any regulatory approvals (where applicable) once available. Your amendment will be reviewed by the REC, as per the attached letter.

When can I implement this amendment?

You may implement this amendment in line with the information in <u>IRAS</u>. Please note that you may only implement changes described in the amendment notice.

Who should I contact if I have further questions about this amendment?

If you have any questions about the ethical review of this amendment, please do not hesitate to contact me

If you have any other questions about this amendment please contact the relevant national coordinating centre for advice:

- England hra.amendments@nhs.net
- Northern Ireland research.gateway@hscni.net
- Scotland nhsg.NRSPCC@nhs.net
- Wales HCRW.amendments@wales.nhs.uk

Additional information on the management of amendments can be found in the IRAS guidance.

Please do not hesitate to contact me if you require further information.

Kind regards

Dr Sarah Graves

Health Research Authority

Ground Floor | Skipton House | 80 London Road | London | SE1 6LH

E.hra.amendments@nhs.net

W. www.hra.nhs.uk

Sign up to receive our newsletter HRA Latest.